Johnson & Johnson Management

Management Kriterienprüfungen 3/4

Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.

Wichtige Informationen

Joaquin Duato

Geschäftsführender

US$13.1m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	11.38%
Amtszeit als Geschäftsführer	2yrs
Eigentum des Geschäftsführers	0.01%
Durchschnittliche Amtszeit des Managements	4.8yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	4.4yrs

Jüngste Management Updates

Recent updates

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Joaquin Duato im Vergleich zu den Einnahmen von Johnson & Johnson verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Oct 01 2023	n/a	n/a	US$14b
Jul 02 2023	n/a	n/a	US$14b
Apr 02 2023	n/a	n/a	US$13b
Jan 01 2023	US$13m	US$1m	US$18b
Oct 02 2022	n/a	n/a	US$18b
Jul 03 2022	n/a	n/a	US$17b
Apr 03 2022	n/a	n/a	US$20b
Jan 02 2022	US$14m	US$1m	US$21b
Oct 03 2021	n/a	n/a	US$18b
Jul 04 2021	n/a	n/a	US$18b
Apr 04 2021	n/a	n/a	US$15b
Jan 03 2021	n/a	n/a	US$15b
Sep 27 2020	n/a	n/a	US$17b
Jun 28 2020	n/a	n/a	US$15b
Mar 29 2020	n/a	n/a	US$17b
Dec 29 2019	US$13m	US$970k	US$15b
Sep 29 2019	n/a	n/a	US$14b
Jun 30 2019	n/a	n/a	US$16b
Mar 31 2019	n/a	n/a	US$15b
Dec 30 2018	US$9m	US$934k	US$15b
Sep 30 2018	n/a	n/a	US$2b
Jul 01 2018	n/a	n/a	US$1b
Apr 01 2018	n/a	n/a	US$1b
Dec 31 2017	US$19m	US$897k	US$1b

Vergütung im Vergleich zum Markt: JoaquinDie Gesamtvergütung ($USD13.10M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt AR ($USD4.93M).

Entschädigung vs. Einkommen: JoaquinDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.

Geschäftsführer

Joaquin Duato (60 yo)

2yrs

Amtszeit

US$13,099,487

Vergütung

Mr. Joaquin Duato serves as Chief Executive Officer & Director of Johnson & Johnson since January 3, 2022 and serves as its Chairman since January 02, 2023. He served as Worldwide Chairman of Pharmaceutica...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Joaquin Duato	CEO & Chairman	2yrs	US$13.10m	0.013% ARS 40.9b
Joseph Wolk	Executive VP & CFO	5.5yrs	US$8.82m	0.0022% ARS 7.0b
Jennifer Taubert	Executive VP & Worldwide Chairman of Innovative Medicine	12yrs	US$8.78m	0.0059% ARS 18.8b
Robert Decker	Controller & Chief Accounting Officer	4.1yrs	keine Daten	0.00073% ARS 2.3b
James Swanson	Executive VP & Chief Information Officer	4.2yrs	keine Daten	0.00038% ARS 1.2b
Jessica Moore	Vice President of Investor Relations	2.2yrs	keine Daten	keine Daten
Dirk Brinckman	Chief Compliance Officer	no data	keine Daten	keine Daten
Elizabeth Forminard	Executive VP & General Counsel	1.3yrs	keine Daten	0.00023% ARS 738.9m
Peter Fasolo	Executive VP & Chief Human Resources Officer	7.8yrs	US$3.62m	0.0043% ARS 13.7b
Guy Lebeau	Group Chairman of MD&D Business - EMEA	no data	keine Daten	keine Daten
William Hait	Executive VP	17yrs	keine Daten	0.0036% ARS 11.6b
Kathryn Wengel	Executive VP and Chief Technical Operations & Risk Officer	5.5yrs	keine Daten	0.0027% ARS 8.8b

4.8yrs

Durchschnittliche Betriebszugehörigkeit

57yo

Durchschnittliches Alter

Erfahrenes Management: DJNJ2Das Führungsteam des Unternehmens gilt als erfahren (4.8 Jahre durchschnittliche Betriebszugehörigkeit).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Joaquin Duato	CEO & Chairman	2yrs	US$13.10m	0.013% ARS 40.9b
D. Davis	Independent Director	9.6yrs	US$350.00k	keine Daten
Anne Mulcahy	Lead Independent Director	15yrs	US$410.00k	0.00033% ARS 1.1b
Hubert Joly	Independent Director	4.1yrs	US$340.00k	0.00021% ARS 674.7m
Marillyn Hewson	Independent Director	4.8yrs	US$353.59k	0.00012% ARS 385.5m
Paula Johnson	Independent Director	less than a year	keine Daten	0% ARS 0
Mark McClellan	Independent Director	10.3yrs	US$320.00k	keine Daten
Mary Beckerle	Independent Director	8.6yrs	US$360.00k	keine Daten
Darius Adamczyk	Independent Director	1.9yrs	US$300.16k	0.000040% ARS 128.5m
Jennifer Doudna	Independent Director	5.8yrs	US$340.00k	keine Daten
Mark Weinberger	Independent Director	4.1yrs	US$340.00k	keine Daten
Nadja West	Independent Director	3.1yrs	US$340.00k	keine Daten

4.4yrs

Durchschnittliche Betriebszugehörigkeit

62.5yo

Durchschnittliches Alter

Erfahrener Vorstand: DJNJ2Die Vorstandsmitglieder gelten als erfahren (4.4 Jahre durchschnittliche Amtszeit).

Unternehmensanalyse und Finanzdaten Status

Daten	Zuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse	2024/01/23 16:50
Aktienkurs zum Tagesende	2023/10/26 00:00
Gewinne	2023/10/01
Jährliche Einnahmen	2023/01/01

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

Paket	Daten	Zeitrahmen	Beispiel US-Quelle ^*
Finanzdaten des Unternehmens	10 Jahre	Gewinn- und Verlustrechnung Kapitalflussrechnung Bilanz	SEC-Formular 10-K SEC-Formular 10-Q
Konsensschätzungen der Analysten	+3 Jahre	Finanzielle Vorausschau Kursziele der Analysten	Analysten Research Berichte Blue Matrix
Marktpreise	30 Jahre	Aktienkurse Dividenden, Splits und Aktionen	ICE-Marktdaten SEC-Formular S-1
Eigentümerschaft	10 Jahre	Top-Aktionäre Insiderhandel	SEC-Formular 4 SEC-Formular 13D
Verwaltung	10 Jahre	Das Führungsteam Direktorium	SEC-Formular 10-K SEC-Formular DEF 14A
Wichtige Entwicklungen	10 Jahre	Ankündigungen des Unternehmens	SEC-Formular 8-K

* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.

Analysemodell und Schneeflocke

Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.

Analysten-Quellen

Johnson & Johnson wird von 53 Analysten beobachtet. 20 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

Analyst	Einrichtung
David Toung	Argus Research Company
Matthew Miksic	Barclays
Lee Hambright	Bernstein

Johnson & Johnson Management

Management Kriterienprüfungen 3/4

Wichtige Informationen

Jüngste Management Updates

Johnson & Johnson, Annual General Meeting, Apr 23, 2026

Johnson & Johnson Elects John Morikis to its Board of Directors and Audit Committee and Compensation & Benefits Committee

Johnson & Johnson Appoints Daniel Pinto to the Board of Directors, Effective July 1, 2025

Recent updates

Johnson & Johnson Receives FDA Approval For Label Expansion Of TREMFYA To Include Inhibition Of Structural Joint Damage In Adults With Active Psoriatic Arthritis

Johnson & Johnson to Report Q2, 2026 Results on Jul 15, 2026

Sieben Alexander, P.A. Secures $10.2 Million Verdict for Twin Cities Family Against Cosmetic Talc Manufacturers Vi-Jon and Four Co-Defendants—Gold Bond, Merck (Dr. Scholl's), Johnson & Johnson, and Perrigo Co. of Tennessee

Johnson & Johnson Announces Global Launch Of Shockwave C2 Aero Coronary IVL Catheter

Johnson & Johnson Announces Positive Phase 3 Fuzion Study Results For Tremfya In Perianal Fistulizing Crohn’s Disease

Johnson & Johnson Shows Greatest Improvement Across Key Efficacy Outcomes for Caplyta (Lumateperone) Among Adjunctive Mdd Treatments in New Network Meta-Analysis

Johnson & Johnson Receives FDA Approval for CAPLYTA Supplemental New Drug Application with Robust New Data Supporting Reduced Risk of Relapse in Schizophrenia

Johnson & Johnson (NYSE:JNJ) has entered into a definitive agreement to acquire Atraverse Medical, Inc.

Johnson & Johnson Showcases CARTO-Powered Innovation, Including Debut of CARTOSOUND SONATA, to Advance Arrhythmia Care at HRS 2026

Johnson & Johnson Raises Quarterly Dividend, Payable on June 9, 2026

Johnson & Johnson Showcases New Clinical Data for TECNIS PureSee IoL at ASCRS 2026 Demonstrating Excellent Contrast Sensitivity and Extended Range of Vision

Johnson & Johnson Launches Varipulse Pro Platform in Europe

Johnson & Johnson Presents One-Year Results for Icotyde in Plaque Psoriasis

Johnson & Johnson Announces FDA Approval Of ICOTYDE™ (icotrokinra) For Plaque Psoriasis Treatment

Johnson & Johnson Highlights Promising First-In-Human Erda-Idrs Results In Intermediate-Risk Non-Muscle-Invasive Bladder Cancer

Johnson & Johnson, Annual General Meeting, Apr 23, 2026

Canada-Wide Talcum Powder Class Action Certified Against Johnson & Johnson

Johnson & Johnson Announces U.S. FDA Approval of TECVAYLI Plus DARZALEX FASPRO For Relapsed/Refractory Multiple Myeloma

Johnson & Johnson Therapy Nipocalimab Granted U.S. FDA Fast Track designation in systemic lupus erythematosus (SLE)

Johnson & Johnson Announces Preliminary Results From Phase 1b Study Of Pasritamig In Combination With Docetaxel In Advanced Prostate Cancer

Blackstone Life Sciences and Johnson & Johnson Announces A Co-Funding Agreement for Acute Myeloid Leukemia

Bayer Files Suit Against Johnson & Johnson (J&J) and Janssen Biotech, Inc

Johnson & Johnson Announces New Long-Term Data from the Quasar Long-Term Extension Study

Johnson & Johnson Reportedly Prepares to Sell Orthopedics Unit for over $20 Billion

Johnson & Johnson Receives U.S. FDA Breakthrough Therapy Designation for Patients with Advanced Head and Neck Cancer

Johnson & Johnson Announces the U.S. Food and Drug Administration Approves a New, Simplified Monthly Dosing Schedule

Philadelphia Jury Returns $250,000 Verdict Against Johnson & Johnson in Latest Baby Powder-Ovarian Cancer Trial

Johnson & Johnson Presents Early Outcomes from the OMNY-AF Pilot Study at 2026 AF Symposium

Johnson & Johnson Announces New Real World Head-To-Head Analysis Demonstrating That Patients with Metastatic Castration-sensitive Prostate Cancer (mCSPC) Initiating ERLEADA®

Johnson & Johnson Announces the U.S. Food and Drug Administration Approval for DARZALEX Faspro (Daratumumab and Hyaluronidase-Fihj) in Combination with Bortezomib, Lenalidomide and Dexamethasone (D-Vrd)

Johnson & Johnson Provides Sales Guidance for the Full Year of 2026

Johnson & Johnson Announces New Analysis of Phase 3 Data Which Found Caplyta®? (Lumateperone) in Combination with an Antibody

Johnson & Johnson Announces Positive Topline Results from the Investigational Phase 3 MajesTEC-9 Study of TECVAYLI (teclistamab-cqyv) Monotherapy

Johnson & Johnson Elevates Leadership in Depression with New Data At 2026 American College of Neuropsychopharmacology Annual Meeting

Johnson & Johnson Announces New Longer Follow-Up Results from the Investigational Phase 1b/2 OrigAMI-1 Study Evaluating amivantamab-vmjw

Johnson & Johnson Submits OTTAVA Robotic Surgical System to the U.S. Food and Drug Administration

Johnson & Johnson Announces Quarterly Dividend for First Quarter 2026, Payable on First Quarter of 2026

Johnson & Johnson (NYSE:JNJ) completed the acquisition of Halda Therapeutics OpCo, Inc.

Minnesota Jury Delivers $65.5 Million History-Making Verdict Against Johnson & Johnson

Los Angeles Jury Delivers $40 Million Verdict Against Johnson & Johnson in Talcum Powder Ovarian Cancer Trial

Johnson & Johnson Announces U.S. Food and Drug Administration Approval of RYBREVANT FASPRO

Johnson & Johnson to Report Q1, 2026 Results on Apr 14, 2026

Johnson & Johnson Announces U.S. Food and Drug Administration Approves AKEEGA as the First Precision Therapy for BRCA2-Mutated Metastatic Castration-sensitive Prostate Cancer with 54% Reduction in Disease Prostate Cancer with 54% reduction in Disease Prostate Cancer

Hagens Berman Sobol Shapiro LLP and Lowey Dannenberg, P.C. Announce Certification of a Class of Third Party Payors Who Purchased or Paid for Some or All of the Price of Stelara

Johnson & Johnson Announces Updated Results For CARVYKTI In Relapsed Or Refractory Multiple Myeloma

Johnson & Johnson's INLEXZO Delivers 74% Disease-Free Survival at One Year in Bcg-Unresponsive, High-Risk, Papillary-Only NMIBC

Johnson & Johnson (NYSE:JNJ) signed a definitive agreement to acquire Halda Therapeutics Opco, Inc. for $3.0 billion.

FDA Approves Darzalex Faspro for Adult Patients with High-Risk Smoldering Multiple Myeloma

Johnson & Johnson Announces U.S. Food and Drug Administration Approval of Caplyta (Lumateperone)

Johnson & Johnson Announces Week 28 Results from Phase 2b ANTHEM-UC Study of Icotrokinra

Johnson & Johnson Announces Findings from the Phase 2 Dahlias Study

Johnson & Johnson Announces New Long-Term Results from the Phase 3 ICONIC-TOTAL Studya Evaluating icotrokinra

TECVAYLI® plus DARZALEX FASPRO® Combination Regimen Significantly Improves Progression-Free Survival and Overall Survival Versus Standard of Care

Johnson & Johnson Declares Dividend for the Fourth Quarter of 2025, Payable on December 9, 2025

Johnson & Johnson Raises Earnings Guidance for 2025

Johnson & Johnson to Showcase New Clinical and Real-World Data on Major Depressive Disorder Portfolio At 2025 ECNP Congress

Johnson & Johnson Announces TREMFYA® (Guselkumab) Is First and Only Il-23 Inhibitor to Demonstrate Sustained Clinical and Endoscopic Outcomes with A Fully Subcutaneous Regimen Through 48 Weeks in Ulcerative Colitis

Johnson & Johnson Announces U.S. Food and Drug Administration Approves Tremfya®? (Guselkumab) for the Treatment of Pediatric Plaque Psoriasis and Active Psoriatic Arritis

Johnson & Johnson Announces U.S. Approval for Subcutaneous Indication in Adults with Ulcerative Colitis

Johnson & Johnson Announces an Investigational Immune-Based Indication Regimen with TECVAYLI®? (Te) and DARZALEX FASPRO®? (Daratumumab andhyaluronidase-fihj) Demonstrated Clinical Trial

Johnson & Johnson Announces New Data from the Phase 3 ICONIC-ADVANCE 1 and 2 Studies

Johnson & Johnson to Showcase Neuropsychiatry Innovations at the 2025 Psych Congress Annual Meeting

Johnson & Johnson Announces U.S. Food and Drug Administration Approves Inlexzo™? (Gemcitabine Intervesical System) Set to Transform How Certain Bladder Cancersare Treated

Johnson & Johnson Elects John Morikis to its Board of Directors and Audit Committee and Compensation & Benefits Committee

Johnson & Johnson Announces Data Publishes in the New England Journal of Medicine Demonstrate RYBREVANT (Amivantamab-Vmjw) Plus LAZCLUZE (Lazertinib) Is Re-Setting Survival Expectations in First-Line EGFR-Mutated Lung Cancer

Johnson & Johnson Announces New Analyses from the Phase 3 Mariposa Study Showing That First-Line Treatment with RYBrevant (Lazertinib) Plus Lazertinib

Johnson & Johnson to Report Q4, 2025 Results on Jan 21, 2026

Johnson & Johnson Unveils Results from the Varipure Substudy of Secure, a Real-World Study on Varipure™? Platform, at 2025 European Society of Cardiology (ESC) Congress

Johnson & Johnson Announces New Data from the DanGer Shock Randomized Control Trial, Published in the New England Journal of Medicine, Confirms the Long-Term Survival Benefit of the Impella CP Heart Pump

Boston Jury Hits Johnson & Johnson with Record $42 Million Verdict in Asbestos Baby Powder Case

Johnson & Johnson Files with U.S. FDA to Include New Evidence in TREMFYA®? (Guselkumab) Label as the Only IL-23 Inhibitor to Demonstrate Significant Inhibitor to Demonstrate Significant Inhibitor of Joint Structural Damage in Active Psoriatic Arthritis

Johnson & Johnson Showcases Latest Advancements in Alzheimer's Research At AAIC 2025